SI-BONE, Inc. (NASDAQ:SIBN) Shares Bought by Fmr LLC

Fmr LLC raised its holdings in shares of SI-BONE, Inc. (NASDAQ:SIBN) by 103.6% in the 3rd quarter, HoldingsChannel reports. The fund owned 2,354 shares of the company’s stock after buying an additional 1,198 shares during the quarter. Fmr LLC’s holdings in SI-BONE were worth $33,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Millrace Asset Group Inc. purchased a new position in SI-BONE in the third quarter valued at approximately $1,056,000. Champlain Investment Partners LLC boosted its holdings in shares of SI-BONE by 14.7% in the 3rd quarter. Champlain Investment Partners LLC now owns 2,800,073 shares of the company’s stock valued at $39,145,000 after buying an additional 358,821 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of SI-BONE by 1.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 315,092 shares of the company’s stock valued at $4,405,000 after buying an additional 5,966 shares during the last quarter. Impax Asset Management Group plc raised its stake in SI-BONE by 41.3% during the 3rd quarter. Impax Asset Management Group plc now owns 758,521 shares of the company’s stock worth $10,604,000 after acquiring an additional 221,604 shares in the last quarter. Finally, Harbor Capital Advisors Inc. lifted its position in SI-BONE by 222.5% in the third quarter. Harbor Capital Advisors Inc. now owns 620,490 shares of the company’s stock valued at $8,674,000 after acquiring an additional 428,110 shares during the last quarter. 98.11% of the stock is owned by institutional investors and hedge funds.

Insider Activity at SI-BONE

In related news, CFO Anshul Maheshwari sold 2,439 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $12.68, for a total value of $30,926.52. Following the completion of the transaction, the chief financial officer now directly owns 194,623 shares of the company’s stock, valued at $2,467,819.64. This trade represents a 1.24 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Anthony J. Recupero sold 3,305 shares of SI-BONE stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $13.58, for a total value of $44,881.90. Following the transaction, the insider now directly owns 233,412 shares of the company’s stock, valued at $3,169,734.96. This trade represents a 1.40 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 21,679 shares of company stock worth $276,439 over the last 90 days. Company insiders own 3.90% of the company’s stock.

SI-BONE Trading Up 0.8 %

NASDAQ:SIBN opened at $13.27 on Thursday. SI-BONE, Inc. has a 1 year low of $11.70 and a 1 year high of $21.70. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.22 and a current ratio of 8.25. The stock has a fifty day moving average price of $13.43 and a two-hundred day moving average price of $14.08. The stock has a market capitalization of $556.52 million, a price-to-earnings ratio of -14.42 and a beta of 1.20.

Analyst Ratings Changes

Several research firms have recently weighed in on SIBN. Needham & Company LLC reissued a “buy” rating and issued a $19.00 target price on shares of SI-BONE in a report on Wednesday, November 20th. Truist Financial lifted their price target on SI-BONE from $16.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $23.00.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.